Drug
Itareparib clinical trials
Also written NMS-03305293.
Keep track of what changes. Save the itareparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- NMS-03305293
- 4
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Nerviano Medical Sciences (4)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses itareparib is read from its arms, and is right about nine times in ten.
Testing it · 4
- Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung CancerRecruitingPhase 1Nerviano Medical SciencesNCT06931626Written as NMS-03305293
- Study of NMS-03305293 in Adult Patients With Relapsed Ovarian CancerRecruitingPhase 1Nerviano Medical SciencesNCT06930755Written as NMS-03305293
- Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaActive, not recruitingPhase 1/2Nerviano Medical SciencesNCT04910022Written as NMS-03305293
- Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid TumorsTerminatedPhase 1Nerviano Medical SciencesNCT04182516Written as NMS-03305293
Codes
What other systems call itareparib · ClinicalTrials.gg INT017065
- UNII (FDA) KFI1190L8LITAREPARIBOne source FDA
- NCI Thesaurus C215740ItareparibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KFI1190L8L | ITAREPARIB | One source FDA |
| NCI Thesaurus | C215740 | Itareparib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.